This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Varinot J, Cussenot O, Roupret M, Conort P, Bitker MO, Chartier-Kastler E, Cheng L, Compérat E (2013) H0XB13 is a sensitive and specific marker of prostate cells, useful in distinguishing between carcinomas of prostatic and urothelial origin. Virchows Arch 463:803–809. https://doi.org/10.1007/s00428-013-1495-0
Larnaudie L, Compérat E, Conort P, Varinot J (2017) HOXB13 a useful marker in pleomorphic giant cell adenocarcinoma of the prostate: a case report and review of the literature. Virchows Arch 471:133–136. https://doi.org/10.1007/s00428-017-2134-y
Miettinen M, McCue PA, Sarlomo-Rikala M (2014) GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors. Am J Surg Pathol 38:13–22. https://doi.org/10.1097/PAS.0b013e3182a0218f.
Barresi V, Ieni A, Cardia R, Licata L, Vitarelli E, Reggiani Bonetti L, Tuccari G (2016) HOXB13 as an immunohistochemical marker of prostatic origin in metastatic tumors. APMIS 124:188–193. https://doi.org/10.1111/apm.12483.
Kristiansen I, Stephan C, Jung K, Dietel M, Rieger A, Tolkach Y, Kristiansen G (2017) Sensitivity of HOXB13 as a diagnostic immunohistochemical marker of prostatic origin in prostate cancer metastases: comparison to PSA, protein, androgen receptor, ERG, NKX3.1, PSAP, and PSMA. Int J Mol Sci 18(6). https://doi.org/10.3390/ijms18061151
Conflict of interest
The authors declare that they have no conflict of interest.
About this article
Cite this article
Varinot, J., Compérat, E. Letter to the editor: reply to Valeria Barresi “HOXB13 is not expressed in pleomorphic giant cell carcinoma of the bladder”. Virchows Arch 473, 261–262 (2018). https://doi.org/10.1007/s00428-018-2395-0